Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and eleven have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $31.75.

Several equities research analysts have recently commented on the company. Stephens increased their price objective on Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a report on Monday, November 17th. Leerink Partners set a $40.00 price target on shares of Immunome in a research report on Monday, December 15th. Lake Street Capital lifted their price objective on shares of Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a research note on Thursday, January 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, January 22nd.

Insider Buying and Selling at Immunome

In related news, Director Isaac Barchas sold 383,200 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the transaction, the director directly owned 2,031,181 shares of the company’s stock, valued at approximately $44,157,874.94. The trade was a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Philip Tsai purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was acquired at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the purchase, the insider owned 43,300 shares in the company, valued at $887,217. This trade represents a 30.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 68,518 shares of company stock worth $1,453,958 over the last 90 days. Company insiders own 7.69% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several institutional investors and hedge funds have recently made changes to their positions in IMNM. Stoneridge Investment Partners LLC grew its holdings in Immunome by 5.4% in the 3rd quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock valued at $143,000 after buying an additional 620 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its holdings in Immunome by 6.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock valued at $128,000 after buying an additional 631 shares during the period. Creative Planning raised its position in Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after purchasing an additional 710 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Immunome by 14.4% during the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after buying an additional 935 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in shares of Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after acquiring an additional 1,167 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Stock Performance

IMNM opened at $21.86 on Tuesday. The business’s 50-day simple moving average is $22.78 and its 200 day simple moving average is $17.32. Immunome has a 52-week low of $5.15 and a 52-week high of $27.65. The firm has a market capitalization of $2.41 billion, a PE ratio of -7.41 and a beta of 2.32.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.